Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation
is brain metastasis (BM)-prone. We determined the impact of this hallmark, along with EGFR …

Background Non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor
receptor (EGFR) mutations often develop brain metastases. Treatment with EGFR-tyrosine …

Background: With the wide application of epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs), the survival of EGFR-mutant non-small-cell lung cancer (NSCLC) …

Background The brain is a common site for metastasis in non-small-cell lung cancer
(NSCLC). This study was designed to evaluate the relationship between the mutational of …

Abstract Comparison of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-
TKI) monotherapy or with bevacizumab in real-world non-small cell lung cancer (NSCLC) …

Brain metastases (BMs) cause morbidity and mortality in patients with non‐small cell lung
cancer (NSCLC). The optimal management of epidermal growth factor receptor (EGFR) …

Objective Brain metastases remain lethal in lung cancer patients. The impacts of epidermal
growth factor receptor (EGFR) mutations and EGFR tyrosine kinase inhibitors (TKIs) on the …

Background Compared with standard chemotherapy, epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) are more effective in patients with advanced non …

Brain metastases are the major cause of life-expectancy shortened for patients with lung
cancer. The prognostic value of EGFR mutation subtypes and survival benefit of EGFR …

Background Lung cancer is the leading cause of cancer-related death worldwide. Up to 85%
of lung cancer is non-small cell lung cancer (NSCLC) and most patients present with …